Identification of COVID-19 Drug Candidates through Computational Drug Repurposing

Henrik Zhang


The recent outbreak of the COVID-19 pandemic has spread from China to the rest of the world in part because the virus has a high infection rate. The lack of a vaccine and ineffective antiviral treatments also contribute to the growing number of those who die from COVID-19. Though vaccines are on the verge of being delivered, drug treatments are still much needed because of the challenge of distributing the vaccine and the month long immunity development period where people remain vulnerable makes drug treatments essential. Drug repurposing reuses previously approved drugs to be used for another disease. Case in point are  Remdesiver and Chloroquine, drugs previously used to treat ebola and malaria, which are now being repurposed to treat COVID-19. In this study, we used a computational approach to identify potential drugs to be repurposed in COVID-19 treatment based on patient genomic data and a public gene drug database. We retrieved datasets containing COVID-19 patient RNA-seq and proteomics data and used it to determine differentially expressed genes in each dataset and their interrupted functional pathways. Through the Drug Gene Interaction database, we found the specific drugs that target each differentially expressed gene and used the evidence scores from the database to create our final network of drug gene interactions. Our network contains a total of 22 unique drugs, 10 of which have been tested in a clinical setting, while the remaining drugs need to be validated in clinical studies in the future.


Drug repurposing, COVID-19, Network, Gene expression, Proteomics, Computational

Full Text:



Platto S, Xue T, and Carafoli E. COVID19: an announced pandemic. Cell Death Dis. 2020, 11(9):799

Mahase E. Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows. BMJ. 2020, 371:m4826

Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020, 370(6520):1110-1115

Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili S-M, Bahreini E. A comprehensive review of COVID-19 characteristics. Biol Proced Online

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020, 323(18):1824-1836

Parvathaneni V, Gupta V. Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. Life Sci. 2020, 259:118275

Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020, 586(7827):113-119

Stolfi P, Manni L, Soligo M, Vergni D, Tieri P. Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19. Front Cell Dev Biol. 2020, 8:545089

Beers B. P-Value Definition. Investopedia.

False Discovery Rate. Columbia Public Health.

Liang L, He Z, Yu H, et al. Selection and Validation of Reference Genes for Gene Expression Studies in Codonopsis pilosula Based on Transcriptome Sequence Data. Sci Rep

Chen JJ, Wang S-J, Tsai C-A, Lin C-J. Selection of differentially expressed genes in microarray data analysis. Pharmacogenomics J. 2007, 7(3):212-220

Oliveros JC. Venny2.1.

Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics J Integr Biol. 2012, 16(5):284-287

QIAGEN Ingenuity Pathway Analysis (QIAGEN IPA). QIAGEN

Griffith M, Griffith OL, Coffman AC, et al. DGIdb: mining the druggable genome. Nat Methods. 2013, 10(12):1209-1210

Baker NC, Ekins S, Williams AJ, Tropsha A. A bibliometric review of drug repurposing. Drug Discov Today. 2018, 23(3):661-672

Mercorelli B, Palù G, Loregian A. Drug Repurposing for Viral Infectious Diseases: How Far Are We? Trends Microbiol. 2018, 26(10):865-876

Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019, 24(10):2076-2085

Ciliberto G, Mancini R, Paggi MG. Drug repurposing against COVID-19: focus on anticancer agents. J Exp Clin Cancer Res CR. 2020, 39(1):86

Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019, 18(1):41-58

Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020, 9(1):761-770

Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020, 181(5):1036-1045.e9

Bojkova D, Klann K, Koch B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020, 583(7816):469-472

Shen B, Yi X, Sun Y, et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell. 2020, 182(1):59-72.e15

Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020, 53:38-42

Castelli V, Cimini A, Ferri C. Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in.” Front Immunol. 2020, 11:2132

Grifoni E, Valoriani A, Cei F, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020, 81(3):452-482

Li H, Xiang X, Ren H, et al. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. J Infect. 2020, 80(6):646-655

D’Alessandro A, Thomas T, Dzieciatkowska M, et al. Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level. J Proteome Res. Published online August 14, 2020

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020, 20(6):363-374

Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. Published online May 15, 2020. doi:10.1016/j.jmii.2020.05.001

Zimmer K. Why Some COVID-19 Cases Are Worse than Others. The Scientist. Published February 24, 2020.

Nguyen DD, Gao K, Chen J, Wang R, Wei G-W. Potentially highly potent drugs for 2019-nCoV. BioRxiv Prepr Serv Biol. Published online February 13, 2020. doi:10.1101/2020.02.05.936013

Rudnicka L, Glowacka P, Goldust M, et al. Cyclosporine therapy during the COVID-19 pandemic. J Am Acad Dermatol. 2020, 83(2):e151-e152

Khalil A, Kamar A, Nemer G. Thalidomide-Revisited: Are C OVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing? Front Immunol. 2020, 11:1248

Vatansev H, Kadiyoran C, Cumhur Cure M, Cure E. COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection. Med Hypotheses. 2020, 143:110091

Polonikov A. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. ACS Infect Dis. 2020, 6(7):1558-1562

Gassen N. Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics. BioRxiv Prepr Serv Biol. Published online April 15, 2020.

Nambou K, Anakpa M. Deciphering the co-adaptation of codon usage between respiratory coronaviruses and their human host uncovers candidate therapeutics for COVID-19. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020, 85:104471

Vatansever EC, Yang K, Kratch KC, et al. Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19. BioRxiv Prepr Serv Biol. Published online May 23, 2020. doi:10.1101/2020.05.23.112235

Alexpandi R, De Mesquita JF, Pandian SK, Ravi AV. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. Front Microbiol. 2020, 11:1796

Cava C, Bertoli G, Castiglioni I. A protein interaction map identifies existing drugs targeting SARS-CoV-2. BMC Pharmacol Toxicol. 2020, 21(1):65

Singh N, Bharara Singh A. S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study. Transl Oncol. 2020, 13(10):100814

Maremanda KP, Sundar IK, Li D, Rahman I. Age-dependent assessment of genes involved in cellular senescence, telomere and mitochondrial pathways in human lung tissue of smokers, COPD and IPF: Associations with SARS-CoV-2 COVID-19 ACE2-TMPRSS2-Furin-DPP4 axis. MedRxiv Prepr Serv Health Sci. Published online June 16, 2020. doi:10.1101/2020.06.14.20129957

Zolfaghari Emameh R, Nosrati H, Eftekhari M, Falak R, Khoshmirsafa M. Expansion of Single Cell Transcriptomics Data of SARS-CoV Infection in Human Bronchial Epithelial Cells to COVID-19. Biol Proced Online. 2020, 22:16

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020, 8(4):e21


Huang S, Zhu B, Cheon IS, et al. PPAR-γ in Macrophages Limits Pulmonary Inflammation and Promotes Host Recovery following Respiratory Viral Infection. J Virol. 2019, 93(9)

Ciavarella C, Motta I, Valente S, Pasquinelli G. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease. Mol Basel Switz. 2020, 25(9)


Schwartz M. Fauci Warns Of “Surge Upon A Surge” As COVID-19 Hospitalizations Hit Yet Another High. NPR.


  • There are currently no refbacks.

AJCMicrob (ISSN 2572-5815) Copyright © 2012-2020. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States